title: Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice.
abstract: In this study, the effects of sitagliptin analogue (SITA) or pioglitazone (PIO) treatment on glucose homeostasis and Β-cell dynamics in animal models of type 2 diabetes--Akita and db/db mice were evaluated. After 4-6 weeks of treatment, both SITA and PIO were shown to lower non-fasting glucose levels and reduced glycemic excursion in the intraperitoneal glucose tolerance test. In addition, both drugs preserved normal islet structure and the proportion of Β-cells in the islets. Compared to the controls, SITA treatment induced a higher Β-cell proliferation rate in Akita mice and a lower rate of apoptosis in db/db mice, whereas PIO treatment induced a lower rate of apoptosis in db/db mice and reduced proliferation rates in Akita mice. In conclusion, both SITA and PIO appear to exert some beneficial effects on the islet structure in addition to glycemic control via different mechanisms that involve Β-cell dynamics in Akita and db/db mice. [BMB reports 2011; 44(11): 713-718].
authors: Division of Endocrinology & Metabolism, Department of Internal Medicine, The Catholic University of Korea, Seoul.
authors: Jin-A
authors: JA
authors: Yeom
authors: Eun Sook
authors: ES
authors: Kim
authors: Heon-Seok
authors: HS
authors: Park
authors: Dong-Sik
authors: DS
authors: Ham
authors: Chenglin
authors: C
authors: Sun
authors: Ji-Won
authors: JW
authors: Kim
authors: Jae-Hyoung
authors: JH
authors: Cho
authors: Kun-Ho
authors: KH
authors: Yoon
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D005215:Fasting / Q000097:blood; D005951:Glucose Tolerance Test; D006706:Homeostasis / Q000187:drug effects; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000473:pathology*; D019394:Ki-67 Antigen / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008820:Mice, Obese; D009765:Obesity / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D009929:Organ Size / Q000187:drug effects; D000077205:Pioglitazone; D011719:Pyrazines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D014230:Triazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D019394:Ki-67 Antigen; D011719:Pyrazines; D045162:Thiazolidinediones; D014230:Triazoles; D000068900:Sitagliptin Phosphate; D000077205:Pioglitazone